Biotest Pharmaceuticals Corporation

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Biotest Pharmaceuticals Corporation sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 5 completed early-phase tilt upper quartile by trial count

Biotest Pharmaceuticals Corporation: 5 sponsored US clinical trials, none currently recruiting.

Biotest Pharmaceuticals Corporation sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hepatitis B Virus Associated Liver Disease, with 1 trials.

Upper-quartile sponsor footprint

Biotest Pharmaceuticals Corporation sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

COMPLETED Phase 3

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

NCT01804829
COMPLETED Phase 1

BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma

NCT01638936
COMPLETED Phase 1

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01001442
COMPLETED Phase 1

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT00723359
COMPLETED Phase 1

Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation

NCT01421212

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 3 1

Therapeutic Areas

Hepatitis B Virus Associated Liver Disease 1
Multiple Myeloma 1

How the Biotest Pharmaceuticals Corporation early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).

Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Hepatitis B Virus Associated Liver Disease (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Biotest Pharmaceuticals Corporation: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Biotest Pharmaceuticals Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Biotest Pharmaceuticals Corporation4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Biotest Pharmaceuticals Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Biotest Pharmaceuticals Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Biotest Pharmaceuticals Corporation page

5 registered trials is a research-attention snapshot, not an endorsement of Biotest Pharmaceuticals Corporation or any single study.

  • None of Biotest Pharmaceuticals Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hepatitis B Virus Associated Liver Disease is the condition Biotest Pharmaceuticals Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hepatitis B Virus Associated Liver Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Biotest Pharmaceuticals Corporation pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.